CoChat

Dasatinib

Lindauer, Markus, Hochhaus, Andreas · 2010 · Recent Results in Cancer Research

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Dasatinib, (former BMS 354825), is an orally available small-molecule multikinase inhibitor. It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-alpha and beta, and ephrin receptor kinase.Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro. The drug has demonstrated activity against clinically relevant mutations, including those associated with poor prognosis during ongoing imatinib therapy.Dasatinib is approved for the treatment of patients with BCR-ABL-positive chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase. It also is approved for the treatment of Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.A single daily dose of 100 mg in chronic phase CML results in high hematologic and molecular remission rates and prolongation of survival. In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended. Complete hematologic and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis. Remissions however are very short.Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions. The role of dasatinib in other diseases, including solid tumors, has to be identified.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-642-01222-8_7

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Research works printed but not linked: 9

  1. Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008:1–8
  2. Evans TRJ, Morgan JA, Van den Abbeele AD, et al (2005) Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol 23:16S:abstr. 3034
  3. Hochhaus A, Neubauer A, Mueller MC, et al (2008b) Imatinib discontinuation after imatinib/interferon alpha combination therapy is associated with continuous responses in the majority of patients. Haematologica 93:abstr. 0927
  4. Jabbour E, Cortes J, O’Brien S et al (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance Semin Hematol 44:25–31
  5. Johnson FM, Chiappori A, Burris H, et al (2007) A phase I study (CA180021-segment 2) of dasatinib in patients (pts) with advanced solid tumors. J Clin Oncol 25:18S:abstr. 14042
  6. Nowell P, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497
  7. Quintas-Cardama A, Kantarjian H, O’Brien S, et al (2007b) Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukaemia. Haematologica 92(Suppl 1):abstr. 0359
  8. Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3907–3915
  9. Yu EY, Wilding G, Posadas E, et al (2008) Dasatinib in patients with hormone refractory progressive prostate cancer: a phase II study. J Clin Oncol 26:15S:abstr. 5165

Cited by

See all 75

Metadata

Authors
Lindauer, M., & Hochhaus, A.
Affiliations
SLK-Kliniken Heilbronn (DE)
Corresponding author
Lindauer, Markus
Venue
Recent Results in Cancer Research
Published
2009-10-07
Volume
184
Pages
83-102
ISSN
0080-0015 (ISSN-L)
OpenAlex
W4256391755
Cited by
57
References
58
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 2 · 2018: 4 · 2017: 2 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 4
FWCI
19.07
Type
book chapter
Language
en
Open access
closed
Licence
Locations
  • Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
dasatinib, BCR-ABL, Src family kinases, multikinase inhibitor, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, imatinib resistance, CD117, PDGFR, cytopenia, pleural effusion, hematologic remission, cytogenetic remission
MeSH terms
Dasatinib, Clinical Trials as Topic, Humans, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Oncogene Proteins v-abl, Proto-Oncogene Proteins c-kit, src-Family Kinases, Receptor, Platelet-Derived Growth Factor alpha, Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib. https://app.cochat.ai/papers/10.1007/978-3-642-01222-8_7
The paper
Lindauer, M., & Hochhaus, A. (2010). Dasatinib. Recent Results in Cancer Research. https://doi.org/10.1007/978-3-642-01222-8_7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.